Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
2.250
+0.170 (8.17%)
At close: Apr 2, 2025, 4:00 PM
2.020
-0.230 (-10.22%)
After-hours: Apr 2, 2025, 6:31 PM EDT
Sunshine Biopharma Revenue
In the year 2024, Sunshine Biopharma had annual revenue of $34.87M with 44.75% growth. Sunshine Biopharma had revenue of $9.59M in the quarter ending December 31, 2024, with 24.93% growth.
Revenue (ttm)
$34.87M
Revenue Growth
+44.75%
P/S Ratio
0.04
Revenue / Employee
$792,597
Employees
44
Market Cap
4.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 34.87M | 10.78M | 44.75% |
| Dec 31, 2023 | 24.09M | 19.75M | 454.42% |
| Dec 31, 2022 | 4.35M | 4.12M | 1,802.41% |
| Dec 31, 2021 | 228.43K | 157.02K | 219.88% |
| Dec 31, 2020 | 71.41K | 50.29K | 238.10% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
SBFM News
- 5 hours ago - Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules - Accesswire
- 6 hours ago - Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug - Benzinga
- 10 hours ago - Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer - Accesswire
- 1 day ago - Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year - Accesswire
- 9 days ago - Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada - Accesswire
- 23 days ago - Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market - Accesswire
- 2 months ago - Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT - Accesswire
- 2 months ago - Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer - Accesswire